Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 36
Encontrada(s) 1 página(s)

Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Rebleeding and mortality risk are increased by ACLF but reduced by pre-emptive TIPS

  • Trebicka, Jonel
  • Cañete Hidalgo, Nuria
  • Bañares, Rafael
  • International Variceal Bleeding Observational Study Group and Baveno Cooperation
Background & aims: The relationship between acute-on-chronic liver failure (ACLF) and acute variceal bleeding (AVB) is poorly understood. Specifically, the prevalence and prognosis of ACLF in the context of AVB is unclear, while the role of transjugular intrahepatic portosystemic shunt (TIPS) in the management in patients with ACLF has not been described to date. Methods: A multicenter, international, observational study was conducted in 2,138 patients from 34 centers between 2011 and 2015. ACLF was defined and graded according to the EASL-CLIF consortium definition. Placement of pre-emptive TIPS (pTIPS) was based on individual center policy. Patients were followed-up for 1 year, until death or liver transplantation. Cox regression and competing risk models (Gray's test) were used to identify independent predictors of rebleeding or mortality. Results: At admission, 380/2,138 (17.8%) patients had ACLF according to EASL-CLIF criteria (grade 1: 38.7%; grade 2: 39.2%; grade 3: 22.1%). The 42-day rebleeding (19% vs. 10%; p <0.001) and mortality (47% vs. 10%; p <0.001) rates were higher in patients with ACLF and increased with ACLF grades. Of note, the presence of ACLF was independently associated with rebleeding and mortality. pTIPS placement improved survival in patients with ACLF at 42 days and 1 year. This effect was also observed in propensity score matching analysis of 66 patients with ACLF, of whom 44 received pTIPs and 22 did not. Conclusions: This large multicenter international real-life study identified ACLF at admission as an independent predictor of rebleeding and mortality in patients with AVB. Moreover, pTIPS was associated with improved survival in patients with ACLF and AVB. Lay summary: Acute variceal bleeding is a deadly complication of liver cirrhosis that results from severe portal hypertension. This study demonstrates that the presence of acute-on-chronic liver failure (ACLF) is the strongest predictor of mortality in patients with acute variceal bleeding. Importantly, patients with ACLF and acute variceal (re)bleeding benefit from pre-emptive (early) placement of a transjugular intrahepatic portosystemic shunt., CIBERehd is funded by Instituto de Salud Carlos III . Juan Carlos Garcia - Pagan is supported by Ministerio de Educacion y Ciencia ( SAF - 2016 - 75767 - R ). Virginia Hernández - Gea is supported by Instituto de Salud Carlos III ( PI14/00182 ). Gilberto Silva - Junior is funded by CAPES Foundation, Ministry of Education of Brazil , Brasilia, Brazil (process number BEX 5960/13 - 4 ). Edilmar Alvarado is supported by a Rio Hortega Fellowship grant form Instituto de Salud Carlos III . Jonel Trebicka is supported by grants from the Deutsche Forschungsgemeinschaft (SFB TRR57 to P18), European Union's Horizon 2020 Research and Innovation Programme ( Galaxy , No. 668031 and MICROB-PREDICT , No. 825694 ) and Societal Challenges - Health, Demographic Change and Wellbeing (No. 731875 ), and Cellex Foundation (PREDICT). Gu W is supported by the China Scholarships Council (CSC: #201906230332 ). Rafael Bañares is funded by Instituto de Salud Carlos III ( PI18/01901 ). Michael Praktiknjo is funded by the Ernst und Berta Grimmke Stiftung (Lfd.Nr. 5/19). The funders had no influence on study design, data collection and analysis, decision to publish or preparation of the manuscript.
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Albumin reprograms the B cell transcriptional landscape and improves neutrophil antimicrobial function in patients with decompensated cirrhosis

  • Clària, Joan
  • Marcos Fa, Xavi
  • Giarracco, Emma
  • Cerutti, Andrea, 1965-
  • Moreau, Richard
Background & aims: Patients with acutely decompensated (AD) cirrhosis are immunocompromised and particularly susceptible to infections. This study investigated the immunomodulatory actions of albumin by which this protein may lower the incidence of infections. Methods: Blood immunophenotyping was performed in 11 patients with AD cirrhosis and 10 healthy volunteers (HV). Bulk and single-cell RNA sequencing (scRNA-seq) and flow cytometry were performed in peripheral blood mononuclear cells (PBMCs) from 20 patients with AD cirrhosis and 34 HV exposed to albumin. Albumin's effects on degranulation, phagocytosis, chemotaxis, and swarming of neutrophils from six patients with AD cirrhosis and nine HV were assessed by measuring myeloperoxidase enzymatic activity, the engulfment of fluorescent-labeled Escherichia coli and zymosan, and interactions of neutrophils with Candida albicans at single-cell resolution in microfluidic chambers, respectively. Whole blood RNA sequencing (RNA-seq) analyses were performed in 49 patients admitted for severe AD cirrhosis, of whom 30 received albumin during hospitalization. Results: Compared with HV, patients with AD cirrhosis showed severe lymphopenia and defective neutrophil antimicrobial function. Bulk and scRNA-seq analyses revealed significantly (false discovery rate [FDR] <0.05) increased signatures related to B cells, myeloid cells, and CD4+ T cells in PBMCs incubated with albumin. Changes in the B cell population were confirmed by flow cytometry. Neutrophils exposed to albumin also exhibited augmented chemotactic and degranulation responses, enhanced phagocytosis, and increased pathogen-restrictive swarming. RNA-seq data analysis in patients who had received albumin revealed specific upregulation of signatures related to B cells and neutrophils together with transcriptional changes in CD4+ T cells (FDR <0.05). Conclusions: The finding that albumin promotes the transcriptional reprogramming and expansion of the B cell compartment and improves neutrophil antimicrobial functions indicates mechanisms that may lower the incidence of infections in patients with severe AD cirrhosis receiving albumin therapy. Impact and implications: Patients with acutely decompensated cirrhosis receiving albumin as treatment have a lower incidence of infections. The reason for this protection is currently unknown, but the present study provides data that support the ability of albumin to boost the antimicrobial functions of immune cells in these patients. Moreover, these findings encourage the design of controlled clinical studies specifically aimed at investigating the effects of albumin administration on the immune system., This research was supported by EF CLIF, a private, non-profit organization receiving unrestricted grants from Grifols and Fundació Privada Cellex. EF CLIF is a partner and/or coordinator of several European Union (EU) Horizon 2020 program projects (Nos. 825694 and 847949). This study was also supported by Ministerio de Ciencia e Innovacion/Agencia Estatal Investigación MCIN/AEI, PID2022-138970OB-I00 10.13039/501100011033/FEDER, UE (to JC) and RTI2018-093894-B-I00 (to AC). LJ-G has held an FPU PhD fellowship (FPU19/04886) from the Spanish Ministry of Science, Innovation and Universities. EW was an EF CLIF Research Fellow who received grants from Fundació Privada Cellex and the Fondation Bettencourt-Schueller. IH received a Marie Skłodowska-Curie grant agreement (No. 75451) from the EU’s Horizon 2020 Research and Innovation Program. The funders had no influence on the study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Dipòsit Digital de la UB
Publication Artículo científico (JournalArticle)

Pathophysiological role of prostanoids in coagulation of the portal venous system in liver cirrhosis

  • Queck, Alexander
  • Thomas, Dominique
  • Jansen, Christian
  • Schreiber, Yannick
  • Rüschenbaum, Sabrina
  • Praktiknjo, Michael
  • Schwarzkopf, Katharina Maria
  • Mücke, Marcus Maximilian
  • Schierwagen, Robert
  • Uschner, Frank Erhard
  • Meyer, Carsten
  • Clària i Enrich, Joan
  • Zeuzem, Stefan
  • Geisslinger, Gerd
  • Trebicka, Jonel
  • Lange, Christian Markus
BACKGROUND: Prostanoids are important regulators of platelet aggregation and thrombotic arterial diseases. Their involvement in the development of portal vein thrombosis, frequent in decompensated liver cirrhosis, is still not investigated. METHODS: Therefore, we used pro-thrombotic venous milieu generation by bare metal stent transjugular intrahepatic portosystemic shunt insertion, to study the role of prostanoids in decompensated liver cirrhosis. Here, 89 patients receiving transjugular intrahepatic portosystemic shunt insertion were included in the study, and baseline levels of thromboxane B2, prostaglandin D2 and prostaglandin E2 were measured in the portal and the hepatic vein. RESULTS: While the hepatic vein contained higher levels of thromboxane B2 than the portal vein, levels of prostaglandin E2 and D2 were higher in the portal vein (all P<0.0001). Baseline concentrations of thromboxane B2 in the portal vein were independently associated with an increase of portal hepatic venous pressure gradient during short term follow-up, as an indirect sign of thrombogenic potential (multivariable P = 0.004). Moreover, severity of liver disease was inversely correlated with portal as well as hepatic vein levels of prostaglandin D2 and E2 (all P<0.0001). CONCLUSIONS: Elevated portal venous thromboxane B2 concentrations are possibly associated with the extent of thrombogenic potential in patients with decompensated liver cirrhosis. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT03584204.
Dipòsit Digital de la UB
Publication Artículo científico (JournalArticle)

The role of macrophage-inducible C-type lectin in different stages of chronic liver disease

  • Schierwagen, Robert
  • Uschner, Frank Erhard
  • Ortiz, Cristina
  • Torres, Sandra
  • Brol, Max J.
  • Tyc, Olaf
  • Gu, Wenyi
  • Grimm, Christian
  • Zeuzem, Stefan
  • Plamper, Andreas
  • Pfeifer, Philipp
  • Zimmer, Sebastian
  • Welsch, Christoph
  • Schaefer, Liliana
  • Rheinwalt, Karl P.
  • Clària i Enrich, Joan
  • Arroyo, Vicente
  • Trebicka, Jonel
  • Klein, Sabine
The macrophage-inducible C-type lectin (mincle) is part of the innate immune system and acts as a pattern recognition receptor for pathogen-associated molecular patterns (PAMPS) and damage-associated molecular patterns (DAMPs). Ligand binding induces mincle activation which consequently interacts with the signaling adapter Fc receptor, SYK, and NF-kappa-B. There is also evidence that mincle expressed on macrophages promotes intestinal barrier integrity. However, little is known about the role of mincle in hepatic fibrosis, especially in more advanced disease stages. Mincle expression was measured in human liver samples from cirrhotic patients and donors collected at liver transplantation and in patients undergoing bariatric surgery. Human results were confirmed in rodent models of cirrhosis and acute-on-chronic liver failure (ACLF). In these models, the role of mincle was investigated in liver samples as well as in peripheral blood monocytes (PBMC), tissues from the kidney, spleen, small intestine, and heart. Additionally, mincle activation was stimulated in experimental non-alcoholic steatohepatitis (NASH) by treatment with mincle agonist trehalose-6,6-dibehenate (TDB). In human NASH, mincle is upregulated with increased collagen production. In ApoE deficient mice fed high-fat western diet (NASH model), mincle activation significantly increases hepatic collagen production. In human cirrhosis, mincle expression is also significantly upregulated. Furthermore, mincle expression is associated with the stage of chronic liver disease. This could be confirmed in rat models of cirrhosis and ACLF. ACLF was induced by LPS injection in cirrhotic rats. While mincle expression and downstream signaling via FC receptor gamma, SYK, and NF-kappa-B are upregulated in the liver, they are downregulated in PBMCs of these rats. Although mincle expressed on macrophages might be beneficial for intestinal barrier integrity, it seems to contribute to inflammation and fibrosis once the intestinal barrier becomes leaky in advanced stages of chronic liver disease.
Dipòsit Digital de la UB
Publication Artículo científico (JournalArticle)

Rebleeding and mortality risk are increased by ACLF but reduced by pre-emptive TIPS

  • Trebicka, Jonel
  • Gu, Wenyi
  • Ibáñez Samaniego, Luis
  • Castellote Alonso, José
  • Silva Junior, Gilberto
  • International Variceal Bleeding Observational Study Group and Baveno Cooperation
Background & Aims: The relationship between acute-on-chronic liver failure (ACLF) and acute variceal bleeding (AVB) is poorly understood. Specifically, the prevalence and prognosis of ACLF in the context of AVB is unclear, while the role of trans-jugular intrahepatic portosystemic shunt (TIPS) in the management in patients with ACLF has not been described to date. Methods: A multicenter, international, observational study was conducted in 2,138 patients from 34 centers between 2011 and 2015. ACLF was defined and graded according to the EASL-CLIF consortium definition. Placement of pre-emptive TIPS (pTIPS) was based on individual center policy. Patients were followed-up for 1 year, until death or liver transplantation. Cox regression and competing risk models (Gray's test) were used to identify independent predictors of rebleeding or mortality. Results: At admission, 380/2,138 (17.8%) patients had ACLF according to EASL-CLIF criteria (grade 1: 38.7%; grade 2: 39.2%; grade 3: 22.1%). The 42-day rebleeding (19% vs. 10%; p<0.001) and mortality (47% vs. 10%; p<0.001) rates were higher in patients with ACLF and increased with ACLF grades. Of note, the presence of ACLF was independently associated with rebleeding and mortality. pTIPS placement improved survival in patients with ACLF at 42 days and 1 year. This effect was also observed in propensity score matching analysis of 66 patients with ACLF, of whom 44 received pTIPs and 22 did not. Conclusions: This large multicenter international real-life study identified ACLF at admission as an independent predictor of rebleeding and mortality inpatients with AVB. Moreover, pTIPS was associated with improved survival in patients with ACLF and AVB. Lay summary: Acute variceal bleeding is a deadly complication of liver cirrhosis that results from severe portal hypertension. This study demonstrates that the presence of acute-on-chronic liver failure (ACLF) is the strongest predictor of mortality in patients with acute variceal bleeding. Importantly, patients with ACLF and acute variceal (re)bleeding benefit from pre-emptive (early) placement of a transjugular intrahepatic portosystemic shunt. (C) 2020 European Association for the Study of the Liver. Published by Elsevier B.V.
Dipòsit Digital de la UB
Publication Artículo científico (JournalArticle)

Targeted lipidomics reveals extensive changes in circulating lipid mediators in patients with acutely decompensated cirrhosis

  • López Vicario, Cristina
  • Checa, Antonio
  • Urdangarin, Arantxa
  • Aguilar, Ferran
  • Alcaraz-Quiles, José
  • Caraceni, Paolo
  • Amorós, Àlex
  • Pavesi, Marco
  • Gomez Cabrero, David
  • Trebicka, Jonel
  • Oettl, Karl
  • Moreau, Richard
  • Planell, Núria
  • Arroyo, Vicente
  • Wheelock, Craig E.
  • Clària i Enrich, Joan
Acute-on-chronic liver failure (ACLF) is a newly described syndrome, which develops in patients with acutely decompensated cirrhosis, and is characterized by intense systemic inflammation, multi-organ failure and high short-term mortality. The profile of circulating lipid mediators, which are endogenous signaling molecules generated from polyunsaturated fatty acids released from membrane phospholipids that play a major role in inflammation and immunity, is poorly characterized in ACLF. In the current study, we assessed the profile of lipid mediators by liquid chromatography coupled to tandem mass spectrometry in plasma from patients with acutely decompensated cirrhosis, with (n=119) and without (n=127) ACLF, and from healthy subjects (HS, n=18). Measurements were prospectively repeated in 191 patients with acutely decompensated cirrhosis during a 28-day follow-up period. Fifty-nine lipid mediators (out of 100) were detected in plasma from cirrhotic patients, of which, 16 were significantly associated with the disease status. Among these, 11 lipid mediators distinguished patients at any stage from HS, whereas two lipid mediators (leukotriene [LT] E4 and 12-hydroxyheptadecatrienoic acid, both derived from arachidonic acid) shaped a minimal plasma fingerprint that discriminated patients with ACLF from those without. Levels of LTE4 distinguished ACLF grade 3 from ACLF grades 1 and 2, followed the clinical course of the disease (increased with worsening and decreased with improvement) and positively correlated with markers of inflammation and non-apoptotic cell death. Moreover, LTE4 together with LXA5 (derived from eicosapentaenoic acid) and EKODE (derived from linoleic acid) associated with short-term mortality. Interestingly, LXA5 and EKODE formed a signature profile associated with coagulation and liver failures. Taken together, these findings uncover specific lipid mediator profiles associated with severity and prognosis of patients with acutely decompensated cirrhosis.
Dipòsit Digital de la UB
Publication Artículo científico (JournalArticle)

Effect of sarcopenia on survival of patients with cirrhosis: A meta-analysis

  • Tantai, Xinxing
  • Liu, Yi
  • Yeo, Yee Hui
  • Praktiknjo, Michael
  • Mauro, Ezequiel
  • Hamaguchi, Yuhei
  • Engelmann, Cornelius
  • Zhang, Peng
  • Jeong, Jae Yoon
  • Van Vugt, Jeroen Laurens Ad
  • Xiao, Huijuan
  • Deng, Huan
  • Gao, Xu
  • Ye, Qing
  • Zhang, Jiayuan
  • Yang, Longbao
  • Cai, Yaqin
  • Liu, Yixin
  • Liu, Na
  • Li, Zongfang
  • Han, Tao
  • Kaido, Toshimi
  • Sohn, Joo Hyun
  • Strassburg, Christian
  • Berg, Thomas
  • Trebicka, Jonel
  • Hsu, Yao Chun
  • IJzermans, Jan Nicolaas Maria
  • Wang, Jinhai
  • Su, Grace L.
  • Ji, Fanpu
  • Nguyen, Mindie H.
The association between sarcopenia and prognosis in patients with cirrhosis remains to be determined. In this study, we aimed to quantify the association between sarcopenia and the risk of mortality in patients with cirrhosis, by sex, underlying liver disease etiology, and severity of hepatic dysfunction.PubMed, Web of Science, EMBASE, and major scientific conference sessions were searched without language restriction through 13 January 2021 with additional manual search of bibliographies of relevant articles. Cohort studies of ?100 patients with cirrhosis and ?12 months of follow-up that evaluated the association between sarcopenia, muscle mass and the risk of mortality were included.22 studies with 6965 patients with cirrhosis were included. The pooled prevalence of sarcopenia in patients with cirrhosis was 37.5% overall (95% CI 32.4%-42.8%), higher in male patients, patients with alcohol associated liver disease (ALD), patients with CTP grade C, and when sarcopenia was defined in patients by lumbar 3- skeletal muscle index (L3-SMI). Sarcopenia was associated with the increased risk of mortality in patients with cirrhosis (adjusted-hazard ratio [aHR] 2.30, 95% CI 2.01-2.63), with similar findings in sensitivity analysis of cirrhosis patients without HCC (aHR 2.35, 95% CI 1.95-2.83) and in subgroup analysis by sex, liver disease etiology, and severity of hepatic dysfunction. The association between quantitative muscle mass index and mortality further supports the poor prognosis for patients with sarcopenia (aHR 0.95, 95% CI 0.93-0.98). There was no significant heterogeneity in all analyses.Sarcopenia was highly and independently associated with higher risk of mortality in patients with cirrhosis.The prevalence of sarcopenia and its association with death in patients with cirrhosis remain unclear. This meta-analysis indicated that sarcopenia affected about one-third of patients with cirrhosis and up to 50% in patients with ALD or Child's class C cirrhosis. Sarcopenia was independently associated with about 2-fold higher risk of mortality in patients with cirrhosis. The mortality rate increased with greater severity or longer period of having sarcopenia. Increasing awareness about the importance of sarcopenia in patients with cirrhosis among stakeholders must be prioritized.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Tutorial: design and fabrication of nanoparticle-based lateral-flow immunoassays

  • Parolo, Claudio
  • Sena-Torralba, Amadeo
  • Bergua, José Francisco
  • Calucho, Enric
  • Fuentes-Chust, Celia
  • Hu, Liming
  • Rivas, Lourdes
  • Álvarez-Diduk, Ruslan
  • Nguyen, Emily P.
  • Cinti, Stefano
  • Quesada-González, Daniel
  • Merkoçi, Arben
Lateral-flow assays (LFAs) are quick, simple and cheap assays to analyze various samples at the point of care or in the field, making them one of the most widespread biosensors currently available. They have been successfully employed for the detection of a myriad of different targets (ranging from atoms up to whole cells) in all type of samples (including water, blood, foodstuff and environmental samples). Their operation relies on the capillary flow of the sample throughout a series of sequential pads, each with different functionalities aiming to generate a signal to indicate the absence/presence (and, in some cases, the concentration) of the analyte of interest. To have a user-friendly operation, their development requires the optimization of multiple, interconnected parameters that may overwhelm new developers. In this tutorial, we provide the readers with: (i) the basic knowledge to understand the principles governing an LFA and to take informed decisions during lateral flow strip design and fabrication, (ii) a roadmap for optimal LFA development independent of the specific application, (iii) a step-by-step example procedure for the assembly and operation of an LF strip for the detection of human IgG and (iv) an extensive troubleshooting section addressing the most frequent issues in designing, assembling and using LFAs. By changing only the receptors, the provided example procedure can easily be adapted for cost-efficient detection of a broad variety of targets., We acknowledge the MICROB-PREDICT project that has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No. 825694. Financial support from the EU Graphene Flagship Core 2 Project (No. 785219) is also acknowledged. This article reflects only the author’s view, and the European Commission is not responsible for any use that may be made of the information it contains. ICN2 is funded by the CERCA programme/Generalitat de Catalunya. The ICN2 is supported by the Severo Ochoa Centres of Excellence programme, funded by the Spanish Research Agency (AEI, grant no. SEV-2017-0706). C.P. acknowledges the Marie Skłodowska-Curie Actions Individual Fellowship; this project has received funding from the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No. 795635. E.C. acknowledges Ministerio de Ciencia e Innovación of Spain and Fondo Social Europeo for the Fellowship PRE2018-084856 awarded under the call ‘Ayudas para contratos predoctorales para la formación de doctores, Subprograma Estatal de Formación del Programa Estatal de Promoción del Talento y su Empleabilidad en I+D+i’, under the framework of ‘Plan Estatal de Investigación Científica y Técnica y de Innovación 2017–2020’. E.P.N. acknowledges funding through the EU’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No. 754510., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

The microbiome meets nanotechnology: Opportunities and challenges in developing new diagnostic devices

  • Fuentes-Chust, Celia
  • Parolo, Claudio
  • Rosati, Giulio
  • Rivas, Lourdes
  • Pérez-Toralla, Karla
  • Simon, Stéphanie
  • Lecuona, Itziar de
  • Junot, Christophe
  • Trebicka, Jonel
  • Merkoçi, Arben
Monitoring of the human microbiome is an emerging area of diagnostics for personalized medicine. Here, the potential of different nanomaterials and nanobiosensing technologies is reviewed for the development of novel diagnostic devices for the detection and measurement of microbiome-related biomarkers. Moreover, the current and future landscape of microbiome-based diagnostics is defined by exploring the advantages and disadvantages of current nanotechnology-based approaches, especially in the context of developing point-of-care (PoC) devices that would meet the international guidelines known as REASSURED (Real-time connectivity; Ease of specimen collection; Affordability; Sensitivity; Specificity; User-friendliness; Rapid & robust operation; Equipment-free; and Deliverability). Finally, the strategies of the latest international scientific consortia working in this field are analyzed, the current microbiome diagnostics market are reported and the principal ethical, legal, and societal issues related to microbiome R&D and innovation are discussed., The MICROB-PREDICT project has received funding from the European Union's Horizon 2020 Research & Innovation Program under grant agreement No 825694. C.P. acknowledges the Marie Skłodowska-Curie Actions Individual Fellowship; this project has received funding from the European Union's Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No. 795635., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Nanodiagnostics to Face SARS-CoV-2 and Future Pandemics: From an Idea to the Market and beyond

  • Rosati, Giulio
  • Idili, Andrea
  • Parolo, Claudio
  • Fuentes-Chust, Celia
  • Calucho, Enric
  • Hu, Liming
  • Castro Silva, Cecilia de Carvalho
  • Rivas, Luis
  • Nguyen, Emily P.
  • Bergua, José Francisco
  • Álvarez-Diduk, Ruslan
  • Muñoz, Jesús
  • Junot, Christophe
  • Penon, O.
  • Monferrer, Dominique
  • Delamarche, Emmanuel
  • Merkoçi, Arben
The COVID-19 pandemic made clear how our society requires quickly available tools to address emerging healthcare issues. Diagnostic assays and devices are used every day to screen for COVID-19 positive patients, with the aim to decide the appropriate treatment and containment measures. In this context, we would have expected to see the use of the most recent diagnostic technologies worldwide, including the advanced ones such as nano-biosensors capable to provide faster, more sensitive, cheaper, and high-throughput results than the standard polymerase chain reaction and lateral flow assays. Here we discuss why that has not been the case and why all the exciting diagnostic strategies published on a daily basis in peer-reviewed journals are not yet successful in reaching the market and being implemented in the clinical practice., We acknowledge funding from the European Union Horizon2020 Programme under Grant No. 881603 (Graphene Flagship Core 3). We acknowledge Consejo Superior de Investigaciones Científicas (CSIC) for the project “COVID19-122” granted in the call “Nuevas ayudas extraordinarias a proyectos de investigación en el marco de las medidas urgentes extraordinarias para hacer frente al impacto económico y social del COVID-19 (Ayudas CSIC–COVID-19)”. We acknowledge the MICROB-PREDICT Project for partially supporting the work. The MICROB-PREDICT project has received funding from the European Union’s Horizon 2020 research and innovation programme under Grant No. 825694. This reflects only the author’s view, and the European Commission is not responsible for any use that may be made of the information it contains. We also acknowledge Agencia Estatal de Investigación (AEI) and Fondo Europeo de Desarrollo Regional (FEDER) for the project MAT2017-87202-P. A.I. was supported by a PROBIST postdoctoral fellowship funded by European Research Council (Marie Skłodowska-Curie Grant No. 754510). C.C.C.S. acknowledges funding through CAPES–PRINT (Programa Institucional de Internacionalização; Grant Nos. 88887.310281/2018-00 and 88887.467442/2019-00) and Mackpesquisa-UPM. L.H. acknowledges funding through the China Scholarship Council. ICN2 is funded by the CERCA Programme/Generalitat de Catalunya and supported by the Severo Ochoa programme (MINECO Grant No. SEV-2017-0706).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Electrochromism: An emerging and promising approach in (bio)sensing technology

  • Farahmand Nejad, Mohammad Amin
  • Ranjbar, Saba
  • Parolo, Claudio
  • Nguyen, Emily P.
  • Álvarez-Diduk, Ruslan
  • Hormozi-Nezhad, Mohammad Reza
  • Merkoçi, Arben
Electrochromism (EC) is a unique property of certain materials that undergo an electrochemical-induced change in colouration. During the last decades, electrochromic materials (ECMs) have been applied in a variety of technologies ranging from smart windows to information displays and energy storage devices. More recently, ECMs have attracted the attention of the (bio)sensing community thanks to their ability to combine the sensitivity of electrochemical methods with the intuitive readout of optical sensors. Although still a nascent technology, EC-based sensors are on the rise with several targets (e.g. cancer biomarkers, bacteria, metabolites and pesticides), which have already been detected by (bio)sensors using ECMs as transducers. In this review, we provide the reader with all the information to understand EC and its use in the development of EC-based biosensors., We acknowledge the MICROB-PREDICT project that has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No. 825694. Financial support from the EU Graphene Flagship Core 2 Project (No. 785219) is also acknowledged. This article reflects only the author’s view, and the European Commission is not responsible for any use that may be made of the information it contains. ICN2 is funded by the CERCA programme, Generalitat de Catalunya. The ICN2 is supported by the Severo Ochoa Centres of Excellence programme, funded by the Spanish Research Agency (AEI, grant no. SEV-2017-0706). E.P.N. acknowledges funding through the EU’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No. 754510.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

A plug, print & play inkjet printing and impedance-based biosensing technology operating through a smartphone for clinical diagnostics

  • Rosati, Giulio
  • Urban, Massimo
  • Zhao, Lei
  • Yang, Qiuyue
  • Castro Silva, Cecilia de Carvalho
  • Bonaldo, Stefano
  • Parolo, Claudio
  • Nguyen, Emily P.
  • Ortega, Gabriel
  • Fornasiero, Pablo
  • Paccagnella, Alessandro
  • Merkoçi, Florind
Simplicity is one of the key feature for the spread of any successful technological product. Here, a method for rapid and low-cost fabrication of electrochemical biosensors is presented. This “plug, print & play” method involves inkjet-printing even in an office-like environment, without the need of highly specialized expertise or equipment, guaranteeing an ultra-fast idea to (scaled) prototype production time. The printed biosensors can be connected to a smartphone through its audio input for their impedance readout, demonstrating the validity of the system for point-of-care biosensing. Proper electrodes layout guarantees high sensitivity and is validated by finite element simulations. The introduction of a passivation method (wax printing) allowed to complete the devices fabrication process, increasing their sensitivity. Indeed, the wax allowed reducing the interference related to the parasitic currents flowing through the permeable coating of the employed substrates, which was used for the chemical sintering, thus avoiding the common thermal treatment after printing. As a case study, we used the devices to develop an electrochemical aptamer-based sensor for the rapid detection of neutrophil gelatinase-associated lipocalin (NGAL) in urine – a clinically important marker of acute kidney injury. The aptasensor platform is capable of detecting clinically relevant concentrations of NGAL with a simple and rapid smartphone readout. The developed technology may be extended in the future to continuous monitoring, taking advantage of its flexibility to integrate it in tubes, or to other diagnostic applications where cost/efficiency and rapidity of the research, development and implementation of point of care devices is a must., The MICROB-PREDICT project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 825694. This reflects only the author's view, and the European Commission is not responsible for any use that may be made of the information it contains. We thank Dr Alex Chamorro and Prof. Kevin Plaxco for the NGAL aptamers sequence used for the case study of our biosensors. E. P. N. acknowledges funding through the EU's Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No. 754510. C.C.C.S. acknowledges funding through CAPES – PRINT (Programa Institucional de Internacionalização; grant #88887.310281/2018-00 and 88887.467442/2019-00) and Mackpesquisa-UPM. This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 101008701 (Project acronym: EMERGE)
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Selection and characterisation of bioreceptors to develop nanoparticle-based lateral-flow immunoassays in the context of the SARS-CoV-2 outbreak

  • Hu, Liming
  • Calucho, Enric
  • Fuentes-Chust, Celia
  • Parolo, Claudio
  • Idili, Andrea
  • Álvarez-Diduk, Ruslan
  • Rivas, Lourdes
  • Merkoçi, Arben
This manuscript aims at raising the attention of the scientific community to the need for better characterised bioreceptors for fast development of point-of-care diagnostic devices able to support mass frequency testing. Particularly, we present the difficulties encountered in finding suitable antibodies for the development of a lateral flow assay for detecting the nucleoprotein of SARS-CoV-2., We acknowledge Consejo Superior de Investigaciones Científicas (CSIC) for the project “COVID19-122” granted in the call “Nuevas ayudas extraordinarias a proyectos de investigación en el marco de las medidas urgentes extraordinarias para hacer frente al impacto económico y social del COVID-19 (Ayudas CSIC-COVID-19)”. We acknowledge also the MICROB-PREDICT project that has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No. 825694. Financial support from the EU Graphene Flagship Core 3 Project (No. 881603) is also acknowledged. This article reflects only the authors' view, and the European Commission is not responsible for any use that may be made of the information it contains. ICN2 is funded by the CERCA programme/Generalitat de Catalunya. ICN2 is supported by the Severo Ochoa Centres of Excellence programme, funded by the Spanish Research Agency (AEI, grant no. SEV-2017-0706). E. C. acknowledges Ministerio de Ciencia e Innovación of Spain and Fondo Social Europeo for the Fellowship PRE2018-084856 awarded under the call ‘Ayudas para contratos predoctorales para la formación de doctores, Subprograma Estatal de Formación del Programa Estatal de Promoción del Talento y su Empleabilidad en I+D+i’, under the framework of ‘Plan Estatal de Investigación Científica y Técnica y de Innovación 2017–2020’. L. H. acknowledges the China Scholarship Council. L. H., E. C. and C. F.-C. acknowledge the Autonomous University of Barcelona (UAB) for their support. C. P. (ISGlobal) also acknowledges support from the Spanish Ministry of Science and Innovation and State Research Agency through the “Centro de Excelencia Severo Ochoa 2019–2023” Program (CEX2018-000806-S), and support from the Generalitat de Catalunya through the CERCA Program. A. I. was supported by a PROBIST postdoctoral fellowship funded by the European Research Council (Marie Skłodowska-Curie grant agreement No. 754510)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Toward next generation lateral flow assays: Integration of nanomaterials

  • Sena-Torralba, Amadeo
  • Álvarez-Diduk, Ruslan
  • Parolo, Claudio
  • Piper, Andrew
  • Merkoçi, Arben
Lateral flow assays (LFAs) are currently the most used point-of-care sensors for both diagnostic (e.g., pregnancy test, COVID-19 monitoring) and environmental (e.g., pesticides and bacterial monitoring) applications. Although the core of LFA technology was developed several decades ago, in recent years the integration of novel nanomaterials as signal transducers or receptor immobilization platforms has brought improved analytical capabilities. In this Review, we present how nanomaterial-based LFAs can address the inherent challenges of point-of-care (PoC) diagnostics such as sensitivity enhancement, lowering of detection limits, multiplexing, and quantification of analytes in complex samples. Specifically, we highlight the strategies that can synergistically solve the limitations of current LFAs and that have proven commercial feasibility. Finally, we discuss the barriers toward commercialization and the next generation of LFAs., We acknowledge financial support to the project AC21_2/00044 (GLEBIOASSAY), funded by Instituto de Salud Carlos III (ISCIII) and cofunded by the European Union, MICROBPREDICT project (European Union Horizon 2020 research and innovation program under grant agreement 825694), and Graphene Flagship Core 3 (European Union Horizon 2020 research and innovation program under grant agreement 881603). ICN2 is funded by CERCA programme, Generalitat de Catalunya. Grant SEV-2017-0706 is funded by MCIN/AEI/10.13039/501100011033. The authors also acknowledge the Project PID2021-124795NB-I00 funded by MCIN/AEI/10.13039/501100011033/and FEDER Una manera de hacer Europa and the project PAPYRUS: Grant PLEC2021-007972 funded by MCIN/AEI/10.13039/501100011033 and by the “European Union NextGenerationEU/PRTR”. The authors acknowledge Consejo Superior de Investigaciones Científicas (CSIC) for the project “COVID19-122” granted in the call “Nuevas ayudas extraordinarias a proyectos de investigación en el marco de las medidas urgentes extraordinarias para hacerfrente al impacto económico y social del COVID-19” (Ayudas CSIC-COVID-19). A.S.-T. acknowledges MINECO for the Juan de la Cierva Formación fellowship (FJC2020-043927-I). C.P. acknowledges the Marie Skłodowska-Curie Actions Individual Fellowship; this project received funding from the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement 795635. C.P. (ISGlobal) also acknowledges support from the Spanish Ministry of Science and Innovation** and State Research Agency through the “Centro de Excelencia Severo Ochoa 2019−2023” Program (CEX2018-000806-S)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Metabolomics for personalized medicine: the input of analytical chemistry from biomarker discovery to point-of-care tests

  • Castelli, Florence Ane
  • Rosati, Giulio
  • Moguet, Christian
  • Fuentes-Chust, Celia
  • Marrugo-Ramírez, José
  • Lefebvre, Thibaud
  • Volland, Hervé
  • Merkoçi, Arben
  • Simon, Stéphanie
  • Fenaille, François
  • Junot, Christophe
Metabolomics refers to the large-scale detection, quantification, and analysis of small molecules (metabolites) in biological media. Although metabolomics, alone or combined with other omics data, has already demonstrated its relevance for patient stratification in the frame of research projects and clinical studies, much remains to be done to move this approach to the clinical practice. This is especially true in the perspective of being applied to personalized/precision medicine, which aims at stratifying patients according to their risk of developing diseases, and tailoring medical treatments of patients according to individual characteristics in order to improve their efficacy and limit their toxicity. In this review article, we discuss the main challenges linked to analytical chemistry that need to be addressed to foster the implementation of metabolomics in the clinics and the use of the data produced by this approach in personalized medicine. First of all, there are already well-known issues related to untargeted metabolomics workflows at the levels of data production (lack of standardization), metabolite identification (small proportion of annotated features and identified metabolites), and data processing (from automatic detection of features to multi-omic data integration) that hamper the inter-operability and reusability of metabolomics data. Furthermore, the outputs of metabolomics workflows are complex molecular signatures of few tens of metabolites, often with small abundance variations, and obtained with expensive laboratory equipment. It is thus necessary to simplify these molecular signatures so that they can be produced and used in the field. This last point, which is still poorly addressed by the metabolomics community, may be crucial in a near future with the increased availability of molecular signatures of medical relevance and the increased societal demand for participatory medicine., Christian Moguet is the recipient of a PhD grant funded by CEA. We acknowledge funding from the MICROB-PREDICT project. The MICROB-PREDICT project has received funding from the European Union’s Horizon 2020 research and innovation program under grant agreement No. 825694.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Janus kinase 2 inhibition by pacritinib as potential therapeutic target for liver fibrosis

  • Torres, Sandra
  • Ortiz, Cristina
  • Bachtler, Nadine
  • Gu, Wenyi
  • Grünewald, Leon D.
  • Kraus, Nico
  • Schierwagen, Robert
  • Hieber, Christoph
  • Meier, Caroline
  • Tyc, Olaf
  • Brol, Maximilian Joseph
  • Uschner, Frank Erhard
  • Nijmeijer, Bart
  • Welsch, Christoph
  • Berres, Marie-Luise
  • García-Ruiz, Carmen
  • Fernández-Checa, José C.
  • Trautwein, Christian
  • Vogl, Thomas J.
  • Zeuzem, Stefan
  • Trebicka, Jonel
  • Klein, Sabine
anus kinase 2 (JAK2) signaling is increased in human and experimental liver fibrosis with portal hypertension. JAK2 inhibitors, such as pacritinib, are already in advanced clinical development for other indications and might also be effective in liver fibrosis. Here, we investigated the antifibrotic role of the JAK2 inhibitor pacritinib on activated hepatic stellate cells (HSCs) in vitro and in two animal models of liver fibrosis in vivo., Jonel Trebicka is supported by the German Research Foundation project ID 403224013–SFB 1382 (A09); by the German Federal Ministry of Education and Research (BMBF) for the DEEP‐HCC project; by the Hessian Ministry of Higher Education, Research, and the Arts (HMWK) for the ENABLE cluster project; and by Eurostars (Grant ID 12350). The MICROB‐PREDICT (project ID 825694), DECISION (project ID 847949), GALAXY (project ID 668031), LIVERHOPE (project ID 731875), and IHMCSA (project ID 964590) projects have received funding from the European Union's Horizon 2020 research and innovation program. The manuscript reflects only the authors' views, and the European Commission is not responsible for any use that may be made of the information it contains. The funders had no influence on study design, data collection and analysis, decision to publish, or preparation of the manuscript.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Palmitoylcarnitine impairs immunity in decompensated cirrhosis

  • Wei Zhang, Ingrid
  • Sánchez-Rodríguez, María Belén
  • López-Vicario, Cristina
  • Casulleras, Mireia
  • Duran-Güell, Marta
  • Flores-Costa, Roger
  • Aguilar, Ferran
  • Rothe, Michael
  • Segalés, Paula
  • García-Ruiz, Carmen
  • Fernández-Checa, José C.
  • Trebicka, Jonel
  • Arroyo, Vicente
  • Clària, Joan
In patients with cirrhosis, acute decompensation (AD) correlates with a hyperinflammatory state driven by mitochondrial dysfunction, which is a significant factor in the progression toward acute-on-chronic liver failure (ACLF). Elevated circulating levels of acylcarnitine, indicative of mitochondrial dysfunction, are predictors of mortality in ACLF patients. Our hypothesis posits that acylcarnitines not only act as biomarkers, but also actively exert detrimental effects on circulating immune cells., Supported by the Plan Nacional de I+D funded by the Agencia Estatal de Investigación (grants PID2019-105240RB-I00 and PID2022-138970OB-I00 [to JC] and PID2019-111669RB-100 and PID2020-115055RB-I00 [to JCF-C]). JC laboratory is a Consolidated Research Group recognised by the Generalitat de Catalunya (2021 SGR 01323) and receives funds from EF CLIF and European Union’s Horizon 2020 research and innovation programme (MICROB-PREDICT [project ID 825694], DECISION [project ID 847949]). JCF-C receives funds from the center grant P50AA011999 Southern California Research Center for ALPD and Cirrhosis funded by NIAAA/NIH, the Project 201916/31 by Fundació Marató TV3 and the European Horizon´s research and innovation program HORIZON-HLTH-2022-STAYHLTH-02 under agreement No 101095679. JT is supported by the German Research Foundation project ID 403224013 – SFB 1382 (A09), by the German Federal Ministry of Education and Research for the DEEP-HCC project and by the Hessian Ministry of Higher Education, Research, the Arts for the ENABLE and ACLF-I cluster projects and the European Union’s Horizon 2020 research and innovation program for MICROB-PREDICT (project ID 825694), DECISION (project ID 847949), GALAXY (project ID 668031), LIVERHOPE (project ID 731875), and IHMCSA (project ID 964590) projects. IWZ was supported by the Sheila Sherlock Post Graduate Programme of the European Association for the Study of the Liver., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Low-cost inkjet-printed nanostructured biosensor based on CRISPR/Cas12a system for pathogen detection

  • Carota, Angela Gilda
  • Bonini, Andrea
  • Urban, Massimo
  • Poma, Noemi
  • Vivaldi, Federico M.
  • Tavanti, Arianna
  • Rossetti, Marianna
  • Rosati, Giulio
  • Merkoçi, Arben
  • Di Francesco, Fabio
The escalating global incidence of infectious diseases caused by pathogenic bacteria, especially in developing countries, emphasises the urgent need for rapid and portable pathogen detection devices. This study introduces a sensitive and specific electrochemical biosensing platform utilising cost-effective electrodes fabricated by inkjet-printing gold and silver nanoparticles on a plastic substrate. The biosensor exploits the CRISPR/Cas12a system for detecting a specific DNA sequence selected from the genome of the target pathogen. Upon detection, the trans-activity of Cas12a/gRNA is triggered, leading to the cleavage of rationally designed single-strand DNA reporters (linear and hairpin) labelled with methylene blue (ssDNA-MB) and bound to the electrode surface. In principle, this sensing mechanism can be adapted to any bacterium by choosing a proper guide RNA to target a specific sequence of its DNA. The biosensor's performance was assessed for two representative pathogens (a Gram-negative, Escherichia coli, and a Gram-positive, Staphylococcus aureus), and results obtained with inkjet-printed gold electrodes were compared with those obtained by commercial screen-printed gold electrodes. Our results show that the use of inkjet-printed nanostructured gold electrodes, which provide a large surface area, in combination with the use of hairpin reporters containing a poly-T loop can increase the sensitivity of the assay corresponding to a signal variation of 86%. DNA targets amplified from various clinically isolated bacteria, have been tested and demonstrate the potential of the proposed platform for point-of-need applications., A.G.C. acknowledges the University of Pisa and the doctoral scholarship in memory of Giulio Regeni. A.B. was supported by the project CRISPRSENSE funded by Tuscany region, Italy (“DECRT. DIRIG. n. 21607 of 29-11-2021”). F.D.F. acknowledges the INSTM three-year project 2021-2024 “Sviluppo di sensori per la misura dell'attività proteasica e l'identificazione di batteri”. The work at ICN2 and the fabrication of the devices was partially funded by project EMERGE. This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 101008701. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union. The European Union can not be held responsible for them. The development of the device fabrication platforms has been partially funded through the MICROB-PREDICT project. The MICROB-PREDICT project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 825694. This reflects only the author's view, and the European Commission is not responsible for any use that may be made of the information it contains. The ICN2 is funded by the CERCA programme/Generalitat de Catalunya. The ICN2 is supported by the Severo Ochoa Centres of Excellence programme, Grant CEX 2021-001214-S, funded by MCIN/AEI/10.13039.501100011033. M.R. is supported by the European Union's Horizon 2020 research and innovation programme under the Marie Sklodowska-Curie grant agreement No 101029884 (SERENA). We acknowledge Departament de Recerca i Universitats of Generalitat de Catalunya for the grant 2021 SGR 01464., With funding from the Spanish government through the "Severo Ochoa Centre of Excellence" accreditation (CEX2021-001214-S)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

The Specific NLRP3 Antagonist IFM-514 Decreases Fibrosis and Inflammation in Experimental Murine Non-Alcoholic Steatohepatitis

  • Torres, Sandra
  • Brol, Maximilian J.
  • Magdaleno, Fernando
  • Schierwagen, Robert
  • Uschner, Frank E.
  • Klein, Sabine
  • Ortiz, Cristina
  • Tyc, Olaf
  • Bachtler, Nadine
  • Stunden, James
  • Bertheloot, Damien
  • Kitanovic, Ana
  • Sanchez, Brian
  • Schrum, Jacob
  • Roush, William R.
  • Franchi, Luigi
  • Byth, Kate
  • Latz, Eicke
  • Trebicka, Jonel
Background and Aims: Activation of the inflammasome NLRP3 (NOD-, LRR- and pyrin domain containing 3) contributes to the development of non-alcoholic fatty liver disease (NAFLD) and progression to non-alcoholic steatohepatitis (NASH). Therefore, this study explored the therapeutic effects of a novel and selective NLRP3 antagonist in a murine dietary model of NASH. Methods: Groups of 12-week-old ApoE -/- mice were fed ad lib for 7 weeks with a methionine/choline deficient (MCD) and western diet (WD). After 3 weeks of diet-induced injury, mice were injected i. p. with the NLRP3 antagonist IFM-514 (100 mg/kg body weight) or vehicle (0.5% carmellose) every day, 5 days/week for a further 4 weeks. Several markers of inflammation, fibrosis and steatosis were evaluated. Whole transcriptome sequencing and panel RNA expression analysis (NanoString) were performed. Results: IFM-514 inhibited IL-1β production in mice challenged with 20 mg/kg lipopolysaccharide, and in mouse and human inflammatory cells in vitro. IFM-514 inhibited hepatic inflammation in the in vivo non-alcoholic steatohepatitis model assessed by H&E staining and in the hepatic gene expression of inflammasome-related proinflammatory cytokines. This effect was associated with significant reduction in caspase-1 activation. Similarly, IFM-514 was efficacious in vivo in MDC-fed ApoE -/- mice, markedly reducing portal pressure, Sirius red staining and 4-hydroxyproline content compared to vehicle-treated mice. Moreover, IFM-514 significantly reduced hepatic steatosis in MCD-fed ApoE -/- mice, as evidenced by NAFLD scores, oil red O staining, hepatic triglycerides and gene expression. In WD treated animals, similar trends in inflammation and fibrosis were observed, although not sufficient IFM-514 levels were reached. Conclusion: Overall, IFM-514 reduced liver inflammation and fibrosis, with mild effects on liver steatosis in experimental murine NASH. Blocking of NLRP3 may be an attractive therapeutic approach for NASH patients., This study received funding from the Deutsche Forschungsgemeinschaft (SFB TRR57 and CRC1382), European Union's Horizon 2020 Research and Innovation Programme (Galaxy, No. 668031, MICROB-PREDICT, No. 825694, and DECISION No. 84794), Societal Challenges-Health, Demographic Change, and Well-Being (No. 731875), Cellex Foundation (PREDICT), LIVERHOPE (No. 731875), Enable (funded by Hessian Ministry of Higher Education, Research, Science and the Arts) and deep-HCC (German Federal Ministry of Education and Research). These funders had no involvement in the design of the study., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Stability matters: evaluating the long-term performance of AuNP-DNA conjugates in lateral flow assays through varied conjugation methods and storage buffers

  • Fuentes-Chust, Celia
  • Parolo, Claudio
  • Piper, Andrew
  • Merkoçi, Arben
This study evaluates five distinct conjugation techniques for attaching DNA to gold nanoparticles (AuNPs), focusing on their applicability in lateral flow assays (LFA). The selected methods include three salt-aging techniques, one polyT-adsorption method, and a rapid butanol dehydration (INDEBT) approach. These methods were chosen based on factors such as popularity, protocol duration, and ionic strength. Additionally, the study investigates the storage stability of DNA–AuNP conjugates in four different buffers: 100 mM Tris-MgCl2, 10 mM PBS-MgCl2, PBS, and deionized water. These buffers were selected to evaluate the effects of ionic strength and their compatibility with LFA materials on conjugate stability and performance. Results indicate that salt-aging methods, particularly with water or PBS, maintained LFA functionality up to 21 days. Adsorbed DNA and all samples stored in PBS-MgCl2 were not functional from the start and aggregated over time. INDEBT and Tris-MgCl2 conjugates demonstrated initial functionality but degraded due to butanol residues and aggregation. A complementary analysis using electrophoretic mobility shift assays (EMSAs), UV-Vis spectroscopy, and dynamic light scattering (DLS) provided essential insights into conjugate behavior. These results emphasize the importance of buffer selection and conjugation techniques for optimizing DNA–AuNP conjugates in LFAs, ensuring their reliability and effectiveness in diagnostic applications., The MICROB-PREDICT project has received funding from the European Union's Horizon 2020 Research & Innovation Program under grant agreement no. 825694. This article reflects only the authors’ view, and the European Commission is not responsible for any use that may be made of the information contained therein. This work was also part funded by the FULLPOC project; AEI Plan Nacional; Grant PID2021-124795NB-I00 funded by MCIN/AEI/ 10.13039/501100011033. at the Catalan Institute of Nanoscience and Nanotechnology (ICN2); The ISGlobal author acknowledges support from the Spanish Ministry of Science and Innovation and State Research Agency through the “Centro de Excelencia Severo Ochoa 2019–2023” Program (CEX2018-000806-S). C.P. acknowledges support from the Spanish Ministry of Science through the Ramón y Cajal grant no. RYC2022-036743-I., With funding from the Spanish government through the "Severo Ochoa Centre of Excelence" accreditation (CEX2018-000806-S), Peer reviewed
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Effect of sarcopenia on survival of patients with cirrhosis: A meta-analysis

  • Tantai, Xinxing
  • Liu, Yi
  • Yeo, Yee Hui
  • Praktiknjo, Michael
  • Mauro, Ezequiel
  • Hamaguchi, Yuhei
  • Engelmann, Cornelius
  • Zhang, Peng
  • Jeong, Jae Yoon
  • Van Vugt, Jeroen Laurens Ad
  • Xiao, Huijuan
  • Deng, Huan
  • Gao, Xu
  • Ye, Qing
  • Zhang, Jiayuan
  • Yang, Longbao
  • Cai, Yaqin
  • Liu, Yixin
  • Liu, Na
  • Li, Zongfang
  • Han, Tao
  • Kaido, Toshimi
  • Sohn, Joo Hyun
  • Strassburg, Christian
  • Berg, Thomas
  • Trebicka, Jonel
  • Hsu, Yao Chun
  • IJzermans, Jan Nicolaas Maria
  • Wang, Jinhai
  • Su, Grace L.
  • Ji, Fanpu
  • Nguyen, Mindie H.
The association between sarcopenia and prognosis in patients with cirrhosis remains to be determined. In this study, we aimed to quantify the association between sarcopenia and the risk of mortality in patients with cirrhosis, by sex, underlying liver disease etiology, and severity of hepatic dysfunction.PubMed, Web of Science, EMBASE, and major scientific conference sessions were searched without language restriction through 13 January 2021 with additional manual search of bibliographies of relevant articles. Cohort studies of ?100 patients with cirrhosis and ?12 months of follow-up that evaluated the association between sarcopenia, muscle mass and the risk of mortality were included.22 studies with 6965 patients with cirrhosis were included. The pooled prevalence of sarcopenia in patients with cirrhosis was 37.5% overall (95% CI 32.4%-42.8%), higher in male patients, patients with alcohol associated liver disease (ALD), patients with CTP grade C, and when sarcopenia was defined in patients by lumbar 3- skeletal muscle index (L3-SMI). Sarcopenia was associated with the increased risk of mortality in patients with cirrhosis (adjusted-hazard ratio [aHR] 2.30, 95% CI 2.01-2.63), with similar findings in sensitivity analysis of cirrhosis patients without HCC (aHR 2.35, 95% CI 1.95-2.83) and in subgroup analysis by sex, liver disease etiology, and severity of hepatic dysfunction. The association between quantitative muscle mass index and mortality further supports the poor prognosis for patients with sarcopenia (aHR 0.95, 95% CI 0.93-0.98). There was no significant heterogeneity in all analyses.Sarcopenia was highly and independently associated with higher risk of mortality in patients with cirrhosis.The prevalence of sarcopenia and its association with death in patients with cirrhosis remain unclear. This meta-analysis indicated that sarcopenia affected about one-third of patients with cirrhosis and up to 50% in patients with ALD or Child's class C cirrhosis. Sarcopenia was independently associated with about 2-fold higher risk of mortality in patients with cirrhosis. The mortality rate increased with greater severity or longer period of having sarcopenia. Increasing awareness about the importance of sarcopenia in patients with cirrhosis among stakeholders must be prioritized.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Pathophysiological role of prostanoids in coagulation of the portal venous system in liver cirrhosis

  • Queck, Alexander
  • Thomas, Dominique
  • Jansen, Christian
  • Schreiber, Yannick
  • Rüschenbaum, Sabrina
  • Praktiknjo, Michael
  • Schwarzkopf, Katharina Maria
  • Mücke, Marcus Maximilian
  • Schierwagen, Robert
  • Uschner, Frank Erhard
  • Meyer, Carsten
  • Clària i Enrich, Joan
  • Zeuzem, Stefan
  • Geisslinger, Gerd
  • Trebicka, Jonel
  • Lange, Christian Markus
BACKGROUND: Prostanoids are important regulators of platelet aggregation and thrombotic arterial diseases. Their involvement in the development of portal vein thrombosis, frequent in decompensated liver cirrhosis, is still not investigated. METHODS: Therefore, we used pro-thrombotic venous milieu generation by bare metal stent transjugular intrahepatic portosystemic shunt insertion, to study the role of prostanoids in decompensated liver cirrhosis. Here, 89 patients receiving transjugular intrahepatic portosystemic shunt insertion were included in the study, and baseline levels of thromboxane B2, prostaglandin D2 and prostaglandin E2 were measured in the portal and the hepatic vein. RESULTS: While the hepatic vein contained higher levels of thromboxane B2 than the portal vein, levels of prostaglandin E2 and D2 were higher in the portal vein (all P<0.0001). Baseline concentrations of thromboxane B2 in the portal vein were independently associated with an increase of portal hepatic venous pressure gradient during short term follow-up, as an indirect sign of thrombogenic potential (multivariable P = 0.004). Moreover, severity of liver disease was inversely correlated with portal as well as hepatic vein levels of prostaglandin D2 and E2 (all P<0.0001). CONCLUSIONS: Elevated portal venous thromboxane B2 concentrations are possibly associated with the extent of thrombogenic potential in patients with decompensated liver cirrhosis. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT03584204.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Albumin reprograms the B cell transcriptional landscape and improves neutrophil antimicrobial function in patients with decompensated cirrhosis

  • Clària, Joan
  • Marcos Fa, Xavi
  • Giarracco, Emma
  • Cerutti, Andrea, 1965-
  • Moreau, Richard
Background & aims: Patients with acutely decompensated (AD) cirrhosis are immunocompromised and particularly susceptible to infections. This study investigated the immunomodulatory actions of albumin by which this protein may lower the incidence of infections. Methods: Blood immunophenotyping was performed in 11 patients with AD cirrhosis and 10 healthy volunteers (HV). Bulk and single-cell RNA sequencing (scRNA-seq) and flow cytometry were performed in peripheral blood mononuclear cells (PBMCs) from 20 patients with AD cirrhosis and 34 HV exposed to albumin. Albumin's effects on degranulation, phagocytosis, chemotaxis, and swarming of neutrophils from six patients with AD cirrhosis and nine HV were assessed by measuring myeloperoxidase enzymatic activity, the engulfment of fluorescent-labeled Escherichia coli and zymosan, and interactions of neutrophils with Candida albicans at single-cell resolution in microfluidic chambers, respectively. Whole blood RNA sequencing (RNA-seq) analyses were performed in 49 patients admitted for severe AD cirrhosis, of whom 30 received albumin during hospitalization. Results: Compared with HV, patients with AD cirrhosis showed severe lymphopenia and defective neutrophil antimicrobial function. Bulk and scRNA-seq analyses revealed significantly (false discovery rate [FDR] <0.05) increased signatures related to B cells, myeloid cells, and CD4+ T cells in PBMCs incubated with albumin. Changes in the B cell population were confirmed by flow cytometry. Neutrophils exposed to albumin also exhibited augmented chemotactic and degranulation responses, enhanced phagocytosis, and increased pathogen-restrictive swarming. RNA-seq data analysis in patients who had received albumin revealed specific upregulation of signatures related to B cells and neutrophils together with transcriptional changes in CD4+ T cells (FDR <0.05). Conclusions: The finding that albumin promotes the transcriptional reprogramming and expansion of the B cell compartment and improves neutrophil antimicrobial functions indicates mechanisms that may lower the incidence of infections in patients with severe AD cirrhosis receiving albumin therapy. Impact and implications: Patients with acutely decompensated cirrhosis receiving albumin as treatment have a lower incidence of infections. The reason for this protection is currently unknown, but the present study provides data that support the ability of albumin to boost the antimicrobial functions of immune cells in these patients. Moreover, these findings encourage the design of controlled clinical studies specifically aimed at investigating the effects of albumin administration on the immune system., This research was supported by EF CLIF, a private, non-profit organization receiving unrestricted grants from Grifols and Fundació Privada Cellex. EF CLIF is a partner and/or coordinator of several European Union (EU) Horizon 2020 program projects (Nos. 825694 and 847949). This study was also supported by Ministerio de Ciencia e Innovacion/Agencia Estatal Investigación MCIN/AEI, PID2022-138970OB-I00 10.13039/501100011033/FEDER, UE (to JC) and RTI2018-093894-B-I00 (to AC). LJ-G has held an FPU PhD fellowship (FPU19/04886) from the Spanish Ministry of Science, Innovation and Universities. EW was an EF CLIF Research Fellow who received grants from Fundació Privada Cellex and the Fondation Bettencourt-Schueller. IH received a Marie Skłodowska-Curie grant agreement (No. 75451) from the EU’s Horizon 2020 Research and Innovation Program. The funders had no influence on the study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Rebleeding and mortality risk are increased by ACLF but reduced by pre-emptive TIPS

  • Trebicka, Jonel
  • Cañete Hidalgo, Nuria
  • Bañares, Rafael
  • International Variceal Bleeding Observational Study Group and Baveno Cooperation
Background & aims: The relationship between acute-on-chronic liver failure (ACLF) and acute variceal bleeding (AVB) is poorly understood. Specifically, the prevalence and prognosis of ACLF in the context of AVB is unclear, while the role of transjugular intrahepatic portosystemic shunt (TIPS) in the management in patients with ACLF has not been described to date. Methods: A multicenter, international, observational study was conducted in 2,138 patients from 34 centers between 2011 and 2015. ACLF was defined and graded according to the EASL-CLIF consortium definition. Placement of pre-emptive TIPS (pTIPS) was based on individual center policy. Patients were followed-up for 1 year, until death or liver transplantation. Cox regression and competing risk models (Gray's test) were used to identify independent predictors of rebleeding or mortality. Results: At admission, 380/2,138 (17.8%) patients had ACLF according to EASL-CLIF criteria (grade 1: 38.7%; grade 2: 39.2%; grade 3: 22.1%). The 42-day rebleeding (19% vs. 10%; p <0.001) and mortality (47% vs. 10%; p <0.001) rates were higher in patients with ACLF and increased with ACLF grades. Of note, the presence of ACLF was independently associated with rebleeding and mortality. pTIPS placement improved survival in patients with ACLF at 42 days and 1 year. This effect was also observed in propensity score matching analysis of 66 patients with ACLF, of whom 44 received pTIPs and 22 did not. Conclusions: This large multicenter international real-life study identified ACLF at admission as an independent predictor of rebleeding and mortality in patients with AVB. Moreover, pTIPS was associated with improved survival in patients with ACLF and AVB. Lay summary: Acute variceal bleeding is a deadly complication of liver cirrhosis that results from severe portal hypertension. This study demonstrates that the presence of acute-on-chronic liver failure (ACLF) is the strongest predictor of mortality in patients with acute variceal bleeding. Importantly, patients with ACLF and acute variceal (re)bleeding benefit from pre-emptive (early) placement of a transjugular intrahepatic portosystemic shunt., CIBERehd is funded by Instituto de Salud Carlos III . Juan Carlos Garcia - Pagan is supported by Ministerio de Educacion y Ciencia ( SAF - 2016 - 75767 - R ). Virginia Hernández - Gea is supported by Instituto de Salud Carlos III ( PI14/00182 ). Gilberto Silva - Junior is funded by CAPES Foundation, Ministry of Education of Brazil , Brasilia, Brazil (process number BEX 5960/13 - 4 ). Edilmar Alvarado is supported by a Rio Hortega Fellowship grant form Instituto de Salud Carlos III . Jonel Trebicka is supported by grants from the Deutsche Forschungsgemeinschaft (SFB TRR57 to P18), European Union's Horizon 2020 Research and Innovation Programme ( Galaxy , No. 668031 and MICROB-PREDICT , No. 825694 ) and Societal Challenges - Health, Demographic Change and Wellbeing (No. 731875 ), and Cellex Foundation (PREDICT). Gu W is supported by the China Scholarships Council (CSC: #201906230332 ). Rafael Bañares is funded by Instituto de Salud Carlos III ( PI18/01901 ). Michael Praktiknjo is funded by the Ernst und Berta Grimmke Stiftung (Lfd.Nr. 5/19). The funders had no influence on study design, data collection and analysis, decision to publish or preparation of the manuscript.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Rebleeding and mortality risk are increased by ACLF but reduced by pre-emptive TIPS

  • Trebicka, Jonel
  • Gu, Wenyi
  • Ibáñez Samaniego, Luis
  • Castellote Alonso, José
  • Silva Junior, Gilberto
  • International Variceal Bleeding Observational Study Group and Baveno Cooperation
Background & Aims: The relationship between acute-on-chronic liver failure (ACLF) and acute variceal bleeding (AVB) is poorly understood. Specifically, the prevalence and prognosis of ACLF in the context of AVB is unclear, while the role of trans-jugular intrahepatic portosystemic shunt (TIPS) in the management in patients with ACLF has not been described to date. Methods: A multicenter, international, observational study was conducted in 2,138 patients from 34 centers between 2011 and 2015. ACLF was defined and graded according to the EASL-CLIF consortium definition. Placement of pre-emptive TIPS (pTIPS) was based on individual center policy. Patients were followed-up for 1 year, until death or liver transplantation. Cox regression and competing risk models (Gray's test) were used to identify independent predictors of rebleeding or mortality. Results: At admission, 380/2,138 (17.8%) patients had ACLF according to EASL-CLIF criteria (grade 1: 38.7%; grade 2: 39.2%; grade 3: 22.1%). The 42-day rebleeding (19% vs. 10%; p<0.001) and mortality (47% vs. 10%; p<0.001) rates were higher in patients with ACLF and increased with ACLF grades. Of note, the presence of ACLF was independently associated with rebleeding and mortality. pTIPS placement improved survival in patients with ACLF at 42 days and 1 year. This effect was also observed in propensity score matching analysis of 66 patients with ACLF, of whom 44 received pTIPs and 22 did not. Conclusions: This large multicenter international real-life study identified ACLF at admission as an independent predictor of rebleeding and mortality inpatients with AVB. Moreover, pTIPS was associated with improved survival in patients with ACLF and AVB. Lay summary: Acute variceal bleeding is a deadly complication of liver cirrhosis that results from severe portal hypertension. This study demonstrates that the presence of acute-on-chronic liver failure (ACLF) is the strongest predictor of mortality in patients with acute variceal bleeding. Importantly, patients with ACLF and acute variceal (re)bleeding benefit from pre-emptive (early) placement of a transjugular intrahepatic portosystemic shunt. (C) 2020 European Association for the Study of the Liver. Published by Elsevier B.V.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Targeted lipidomics reveals extensive changes in circulating lipid mediators in patients with acutely decompensated cirrhosis

  • López Vicario, Cristina
  • Checa, Antonio
  • Urdangarin, Arantxa
  • Aguilar, Ferran
  • Alcaraz-Quiles, José
  • Caraceni, Paolo
  • Amorós, Àlex
  • Pavesi, Marco
  • Gomez Cabrero, David
  • Trebicka, Jonel
  • Oettl, Karl
  • Moreau, Richard
  • Planell, Núria
  • Arroyo, Vicente
  • Wheelock, Craig E.
  • Clària i Enrich, Joan
Acute-on-chronic liver failure (ACLF) is a newly described syndrome, which develops in patients with acutely decompensated cirrhosis, and is characterized by intense systemic inflammation, multi-organ failure and high short-term mortality. The profile of circulating lipid mediators, which are endogenous signaling molecules generated from polyunsaturated fatty acids released from membrane phospholipids that play a major role in inflammation and immunity, is poorly characterized in ACLF. In the current study, we assessed the profile of lipid mediators by liquid chromatography coupled to tandem mass spectrometry in plasma from patients with acutely decompensated cirrhosis, with (n=119) and without (n=127) ACLF, and from healthy subjects (HS, n=18). Measurements were prospectively repeated in 191 patients with acutely decompensated cirrhosis during a 28-day follow-up period. Fifty-nine lipid mediators (out of 100) were detected in plasma from cirrhotic patients, of which, 16 were significantly associated with the disease status. Among these, 11 lipid mediators distinguished patients at any stage from HS, whereas two lipid mediators (leukotriene [LT] E4 and 12-hydroxyheptadecatrienoic acid, both derived from arachidonic acid) shaped a minimal plasma fingerprint that discriminated patients with ACLF from those without. Levels of LTE4 distinguished ACLF grade 3 from ACLF grades 1 and 2, followed the clinical course of the disease (increased with worsening and decreased with improvement) and positively correlated with markers of inflammation and non-apoptotic cell death. Moreover, LTE4 together with LXA5 (derived from eicosapentaenoic acid) and EKODE (derived from linoleic acid) associated with short-term mortality. Interestingly, LXA5 and EKODE formed a signature profile associated with coagulation and liver failures. Taken together, these findings uncover specific lipid mediator profiles associated with severity and prognosis of patients with acutely decompensated cirrhosis.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

The role of macrophage-inducible C-type lectin in different stages of chronic liver disease

  • Schierwagen, Robert
  • Uschner, Frank Erhard
  • Ortiz, Cristina
  • Torres, Sandra
  • Brol, Max J.
  • Tyc, Olaf
  • Gu, Wenyi
  • Grimm, Christian
  • Zeuzem, Stefan
  • Plamper, Andreas
  • Pfeifer, Philipp
  • Zimmer, Sebastian
  • Welsch, Christoph
  • Schaefer, Liliana
  • Rheinwalt, Karl P.
  • Clària i Enrich, Joan
  • Arroyo, Vicente
  • Trebicka, Jonel
  • Klein, Sabine
The macrophage-inducible C-type lectin (mincle) is part of the innate immune system and acts as a pattern recognition receptor for pathogen-associated molecular patterns (PAMPS) and damage-associated molecular patterns (DAMPs). Ligand binding induces mincle activation which consequently interacts with the signaling adapter Fc receptor, SYK, and NF-kappa-B. There is also evidence that mincle expressed on macrophages promotes intestinal barrier integrity. However, little is known about the role of mincle in hepatic fibrosis, especially in more advanced disease stages. Mincle expression was measured in human liver samples from cirrhotic patients and donors collected at liver transplantation and in patients undergoing bariatric surgery. Human results were confirmed in rodent models of cirrhosis and acute-on-chronic liver failure (ACLF). In these models, the role of mincle was investigated in liver samples as well as in peripheral blood monocytes (PBMC), tissues from the kidney, spleen, small intestine, and heart. Additionally, mincle activation was stimulated in experimental non-alcoholic steatohepatitis (NASH) by treatment with mincle agonist trehalose-6,6-dibehenate (TDB). In human NASH, mincle is upregulated with increased collagen production. In ApoE deficient mice fed high-fat western diet (NASH model), mincle activation significantly increases hepatic collagen production. In human cirrhosis, mincle expression is also significantly upregulated. Furthermore, mincle expression is associated with the stage of chronic liver disease. This could be confirmed in rat models of cirrhosis and ACLF. ACLF was induced by LPS injection in cirrhotic rats. While mincle expression and downstream signaling via FC receptor gamma, SYK, and NF-kappa-B are upregulated in the liver, they are downregulated in PBMCs of these rats. Although mincle expressed on macrophages might be beneficial for intestinal barrier integrity, it seems to contribute to inflammation and fibrosis once the intestinal barrier becomes leaky in advanced stages of chronic liver disease.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Tutorial, design and fabrication of nanoparticle-based lateral-flow immunoassays

  • Parolo, Claudio|||0000-0001-9481-4408
  • Sena-Torralba, Amadeo|||0000-0003-1340-1383
  • Bergua Canudo, José Francisco|||0000-0002-5969-193X
  • Calucho, Enric|||0000-0002-6024-765X
  • Fuentes-Chust, Celia|||0000-0002-8945-8514
  • Hu, Liming|||0000-0002-8666-9287
  • Rivas, Lourdes|||0000-0002-1510-5927
  • Álvarez Diduk, Ruslan|||0000-0002-9876-1574
  • Nguyen, Emily P.|||0000-0003-4299-2055
  • Cinti, Stefano|||0000-0002-8274-7452
  • Quesada-González, Daniel|||0000-0003-3064-2146
  • Merkoçi, Arben|||0000-0003-2486-8085
Lateral-flow assays (LFAs) are quick, simple and cheap assays to analyze various samples at the point of care or in the field, making them one of the most widespread biosensors currently available. They have been successfully employed for the detection of a myriad of different targets (ranging from atoms up to whole cells) in all type of samples (including water, blood, foodstuff and environmental samples). Their operation relies on the capillary flow of the sample throughout a series of sequential pads, each with different functionalities aiming to generate a signal to indicate the absence/presence (and, in some cases, the concentration) of the analyte of interest. To have a user-friendly operation, their development requires the optimization of multiple, interconnected parameters that may overwhelm new developers. In this tutorial, we provide the readers with: (i) the basic knowledge to understand the principles governing an LFA and to take informed decisions during lateral flow strip design and fabrication, (ii) a roadmap for optimal LFA development independent of the specific application, (iii) a step-by-step example procedure for the assembly and operation of an LF strip for the detection of human IgG and (iv) an extensive troubleshooting section addressing the most frequent issues in designing, assembling and using LFAs. By changing only the receptors, the provided example procedure can easily be adapted for cost-efficient detection of a broad variety of targets.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Nanodiagnostics to face SARS-CoV-2 and future pandemics, from an idea to the market and beyond

  • Rosati, Giulio|||0000-0002-0227-4561
  • Idili, Andrea|||0000-0002-6004-270X
  • Parolo, Claudio|||0000-0001-9481-4408
  • Fuentes-Chust, Celia|||0000-0002-8945-8514
  • Calucho, Enric|||0000-0002-6024-765X
  • Hu, Liming|||0000-0002-8666-9287
  • De Carvalho Castro Silva, Cecilia|||0000-0003-3933-1838
  • Rivas, Lourdes|||0000-0002-1510-5927
  • Nguyen, Emily P.|||0000-0003-4299-2055
  • Bergua Canudo, José Francisco|||0000-0002-5969-193X
  • Álvarez Diduk, Ruslan|||0000-0002-9876-1574
  • Muñoz, Jose|||0000-0001-9529-6980
  • Junot, Christophe
  • Penon, Oriol|||0000-0003-0811-9631
  • Monferrer, Dominique
  • Delamarche, Emmanuel|||0000-0002-8753-8895
  • Merkoçi, Arben|||0000-0003-2486-8085
The COVID-19 pandemic made clear how our society requires quickly available tools to address emerging healthcare issues. Diagnostic assays and devices are used every day to screen for COVID-19 positive patients, with the aim to decide the appropriate treatment and containment measures. In this context, we would have expected to see the use of the most recent diagnostic technologies worldwide, including the advanced ones such as nano-biosensors capable to provide faster, more sensitive, cheaper, and high-throughput results than the standard polymerase chain reaction and lateral flow assays. Here we discuss why that has not been the case and why all the exciting diagnostic strategies published on a daily basis in peer-reviewed journals are not yet successful in reaching the market and being implemented in the clinical practice.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

A plug, print & play inkjet printing and impedance-based biosensing technology operating through a smartphone for clinical diagnostics

  • Rosati, Giulio|||0000-0002-0227-4561
  • Urban, Massimo|||0000-0001-6083-833X
  • Zhao, Lei|||0000-0003-0291-2655
  • Yang, Qiuyue|||0000-0002-7693-6679
  • De Carvalho Castro Silva, Cecilia|||0000-0003-3933-1838
  • Bonaldo, Stefano|||0000-0003-0712-5036
  • Parolo, Claudio|||0000-0001-9481-4408
  • Nguyen, Emily P.|||0000-0003-4299-2055
  • Ortega, Gabriel
  • Fornasiero, Paolo|||0000-0003-1082-9157
  • Paccagnella, Alessandro|||0000-0002-6850-4286
  • Merkoçi, Arben|||0000-0003-2486-8085
Simplicity is one of the key feature for the spread of any successful technological product. Here, a method for rapid and low-cost fabrication of electrochemical biosensors is presented. This "plug, print & play" method involves inkjet-printing even in an office-like environment, without the need of highly specialized expertise or equipment, guaranteeing an ultra-fast idea to (scaled) prototype production time. The printed biosensors can be connected to a smartphone through its audio input for their impedance readout, demonstrating the validity of the system for point-of-care biosensing. Proper electrodes layout guarantees high sensitivity and is validated by finite element simulations. The introduction of a passivation method (wax printing) allowed to complete the devices fabrication process, increasing their sensitivity. Indeed, the wax allowed reducing the interference related to the parasitic currents flowing through the permeable coating of the employed substrates, which was used for the chemical sintering, thus avoiding the common thermal treatment after printing. As a case study, we used the devices to develop an electrochemical aptamer-based sensor for the rapid detection of neutrophil gelatinase-associated lipocalin (NGAL) in urine - a clinically important marker of acute kidney injury. The aptasensor platform is capable of detecting clinically relevant concentrations of NGAL with a simple and rapid smartphone readout. The developed technology may be extended in the future to continuous monitoring, taking advantage of its flexibility to integrate it in tubes, or to other diagnostic applications where cost/efficiency and rapidity of the research, development and implementation of point of care devices is a must.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Metabolomics for personalized medicine, the input of analytical chemistry from biomarker discovery to point-of-care tests

  • Castelli, Florence Anne
  • Rosati, Giulio|||0000-0002-0227-4561
  • Moguet, Christian
  • Fuentes-Chust, Celia|||0000-0002-8945-8514
  • Marrugo-Ramirez, Jose|||0000-0001-6275-5503
  • Lefebvre, Thibaud
  • Volland, Hervé
  • Merkoçi, Arben|||0000-0003-2486-8085
  • Simon, Stéphanie
  • Fenaille, François|||0000-0001-6787-4149
  • Junot, Christophe
Metabolomics refers to the large-scale detection, quantification, and analysis of small molecules (metabolites) in biological media. Although metabolomics, alone or combined with other omics data, has already demonstrated its relevance for patient stratification in the frame of research projects and clinical studies, much remains to be done to move this approach to the clinical practice. This is especially true in the perspective of being applied to personalized/precision medicine, which aims at stratifying patients according to their risk of developing diseases, and tailoring medical treatments of patients according to individual characteristics in order to improve their efficacy and limit their toxicity. In this review article, we discuss the main challenges linked to analytical chemistry that need to be addressed to foster the implementation of metabolomics in the clinics and the use of the data produced by this approach in personalized medicine. First of all, there are already well-known issues related to untargeted metabolomics workflows at the levels of data production (lack of standardization), metabolite identification (small proportion of annotated features and identified metabolites), and data processing (from automatic detection of features to multi-omic data integration) that hamper the inter-operability and reusability of metabolomics data. Furthermore, the outputs of metabolomics workflows are complex molecular signatures of few tens of metabolites, often with small abundance variations, and obtained with expensive laboratory equipment. It is thus necessary to simplify these molecular signatures so that they can be produced and used in the field. This last point, which is still poorly addressed by the metabolomics community, may be crucial in a near future with the increased availability of molecular signatures of medical relevance and the increased societal demand for participatory medicine.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

The Microbiome Meets Nanotechnology, Opportunities and Challenges in Developing New Diagnostic Devices

  • Fuentes-Chust, Celia|||0000-0002-8945-8514
  • Parolo, Claudio|||0000-0001-9481-4408
  • Rosati, Giulio|||0000-0002-0227-4561
  • Rivas, Lourdes|||0000-0002-1510-5927
  • Perez-Toralla, Karla|||0000-0003-1980-3068
  • Simon, Stéphanie
  • Lecuona, Itziar de|||0000-0002-5081-5756
  • Junot, Christophe
  • Trebicka, Jonel|||0000-0002-7028-3881
  • Merkoçi, Arben|||0000-0003-2486-8085
Monitoring of the human microbiome is an emerging area of diagnostics for personalized medicine. Here, the potential of different nanomaterials and nanobiosensing technologies is reviewed for the development of novel diagnostic devices for the detection and measurement of microbiome-related biomarkers. Moreover, the current and future landscape of microbiome-based diagnostics is defined by exploring the advantages and disadvantages of current nanotechnology-based approaches, especially in the context of developing point-of-care (PoC) devices that would meet the international guidelines known as REASSURED (Real-time connectivity; Ease of specimen collection; Affordability; Sensitivity; Specificity; User-friendliness; Rapid & robust operation; Equipment-free; and Deliverability). Finally, the strategies of the latest international scientific consortia working in this field are analyzed, the current microbiome diagnostics market are reported and the principal ethical, legal, and societal issues related to microbiome R&D and innovation are discussed.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Toward Next Generation Lateral Flow Assays, Integration of Nanomaterials

  • Sena-Torralba, Amadeo|||0000-0003-1340-1383
  • Álvarez Diduk, Ruslan|||0000-0002-9876-1574
  • Parolo, Claudio|||0000-0001-9481-4408
  • Piper, Andrew|||0000-0002-1208-8009
  • Merkoçi, Arben|||0000-0003-2486-8085
Lateral flow assays (LFAs) are currently the most used point-of-care sensors for both diagnostic (e.g., pregnancy test, COVID-19 monitoring) and environmental (e.g., pesticides and bacterial monitoring) applications. Although the core of LFA technology was developed several decades ago, in recent years the integration of novel nanomaterials as signal transducers or receptor immobilization platforms has brought improved analytical capabilities. In this Review, we present how nanomaterial-based LFAs can address the inherent challenges of point-of-care (PoC) diagnostics such as sensitivity enhancement, lowering of detection limits, multiplexing, and quantification of analytes in complex samples. Specifically, we highlight the strategies that can synergistically solve the limitations of current LFAs and that have proven commercial feasibility. Finally, we discuss the barriers toward commercialization and the next generation of LFAs.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Selection and characterisation of bioreceptors to develop nanoparticle-based lateral-flow immunoassays in the context of the SARS-CoV-2 outbreak

  • Hu, Liming|||0000-0002-8666-9287
  • Calucho, Enric|||0000-0002-6024-765X
  • Fuentes-Chust, Celia|||0000-0002-8945-8514
  • Parolo, Claudio|||0000-0001-9481-4408
  • Idili, Andrea|||0000-0002-6004-270X
  • Álvarez Diduk, Ruslan|||0000-0002-9876-1574
  • Rivas, Lourdes|||0000-0002-1510-5927
  • Merkoçi, Arben|||0000-0003-2486-8085
This manuscript aims at raising the attention of the scientific community to the need for better characterised bioreceptors for fast development of point-of-care diagnostic devices able to support mass frequency testing. Particularly, we present the difficulties encountered in finding suitable antibodies for the development of a lateral flow assay for detecting the nucleoprotein of SARS-CoV-2.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Laser Reduced Graphene Oxide Electrode for Pathogenic Escherichia coli Detection

  • Zhao, Lei|||0000-0003-0291-2655
  • Rosati, Giulio|||0000-0002-0227-4561
  • Piper, Andrew|||0000-0002-1208-8009
  • De Carvalho Castro Silva, Cecilia|||0000-0003-3933-1838
  • Hu, Liming|||0000-0002-8666-9287
  • Yang, Qiuyue|||0000-0002-7693-6679
  • Della Pelle, Flavio|||0000-0002-8877-7580
  • Álvarez Diduk, Ruslan|||0000-0002-9876-1574
  • Merkoçi, Arben|||0000-0003-2486-8085
Graphene-based materials are of interest in electrochemical biosensing due to their unique properties, such as high surface areas, unique electrochemical properties, and biocompatibility. However, the scalable production of graphene electrodes remains a challenge; it is typically slow, expensive, and inefficient. Herein, we reported a simple, fast, and maskless method for large-scale, low-cost reduced graphene oxide electrode fabrication; using direct writing (laser scribing and inkjet printing) coupled with a stamp-transferring method. In this process, graphene oxide is simultaneously reduced and patterned with a laser, before being press-stamped onto polyester sheets. The transferred electrodes were characterized by SEM, XPS, Raman, and electrochemical methods. The biosensing utility of the electrodes was demonstrated by developing an electrochemical test for Escherichia coli. These biosensors exhibited a wide dynamic range (917-2.1 × 10 7 CFU/mL) of low limits of detection (283 CFU/mL) using just 5 μL of sample. The test was also verified in spiked artificial urine, and the sensor was integrated into a portable wireless system driven and measured by a smartphone. This work demonstrates the potential to use these biosensors for real-world, point-of-care applications. Hypothetically, the devices are suitable for the detection of other pathogenic bacteria.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Low-cost inkjet-printed nanostructured biosensor based on CRISPR/Cas12a system for pathogen detection

  • Carota, Angela Gilda
  • Bonini, A|||0000-0001-9511-0699
  • Urban, Massimo|||0000-0001-6083-833X
  • Poma, Noemi
  • Vivaldi, Federico Maria
  • Tavanti, Arianna
  • Rossetti, Marianna|||0000-0001-5711-1287
  • Rosati, Giulio|||0000-0002-0227-4561
  • Merkoçi, Arben|||0000-0003-2486-8085
  • Di Francesco, Fabio|||0000-0002-9285-1595
The escalating global incidence of infectious diseases caused by pathogenic bacteria, especially in developing countries, emphasises the urgent need for rapid and portable pathogen detection devices. This study introduces a sensitive and specific electrochemical biosensing platform utilising cost-effective electrodes fabricated by inkjet-printing gold and silver nanoparticles on a plastic substrate. The biosensor exploits the CRISPR/Cas12a system for detecting a specific DNA sequence selected from the genome of the target pathogen. Upon detection, the trans-activity of Cas12a/gRNA is triggered, leading to the cleavage of rationally designed single-strand DNA reporters (linear and hairpin) labelled with methylene blue (ssDNA-MB) and bound to the electrode surface. In principle, this sensing mechanism can be adapted to any bacterium by choosing a proper guide RNA to target a specific sequence of its DNA. The biosensor's performance was assessed for two representative pathogens (a Gram-negative, Escherichia coli, and a Gram-positive, Staphylococcus aureus), and results obtained with inkjet-printed gold electrodes were compared with those obtained by commercial screen-printed gold electrodes. Our results show that the use of inkjet-printed nanostructured gold electrodes, which provide a large surface area, in combination with the use of hairpin reporters containing a poly-T loop can increase the sensitivity of the assay corresponding to a signal variation of 86%. DNA targets amplified from various clinically isolated bacteria, have been tested and demonstrate the potential of the proposed platform for point-of-need applications.